September 26th 2025
The 100% tariff on imported drugs will pressure pharma companies to build manufacturing sites in the US or face significant costs.
Pharma Supply Chains: Contingency Planning Not Yet a Priority, Survey Says
November 20th 2015UPS’ 2015 “Pain in the Chain” survey suggests that pharma companies are getting better at product protection, cold chain and regulatory compliance, but need to improve cost control and planning for unexpected events. Lack of transparency and “too many handoffs” remain major challenges.